More Obesity Drugs In The Pipeline
January 20, 2024 Novo Nordisk and Eli Lilly aren’t the only drug companies active in the prescription diet drugs space. Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related […]
More Obesity Drugs In The Pipeline Read More »